MELISSA at Diatec 2026: Breakthroughs in Personalising Diabetes Care

On 23 January 2026, Diatec took place in Berlin. MELISSA was presented by Stavroula Mougiakakou (UBERN) as part of the panel “Breakthrough Projekte aus der DACH-Region” (Breakthrough Projects from Germany, Austria and Switzerland). The session highlighted how artificial intelligence and interoperability can reduce the daily treatment burden and enhance clinical decision-making for people living with diabetes.

Diatec, an annual conference dedicated to digitalisation in diabetes care, brought together researchers, industry, healthcare stakeholders and people with diabetes. This year’s programme placed a strong emphasis on interoperability, a topic of growing importance as continuous glucose monitoring and automated insulin delivery systems become increasingly embedded in everyday care.

During her presentation, Stavroula Mougiakakou demonstrated how MELISSA supports adaptive, individualised insulin decision-making by applying reinforcement learning. This approach marks a shift away from rigid, device-centred models towards dynamic, data-driven decision support. Alongside MELISSA, two other EU-funded projects, PRAESIIDIUM and MuSiC4Diabetes, presented their latest results.

“MELISSA provides clinical validation of reinforcement learning for personalised insulin decision-making at scale. It contributes to the transition from rigid, device-centred diabetes care to adaptive, data-driven decision support,” summarises Mougiakakou.

MELISSA’s presence at Diatec 2026 underlines its role in advancing next-generation diabetes care and demonstrates how AI-supported, interoperable solutions can pave the way for more personalised, effective and scalable treatment strategies across Europe.

Diatech 2026

Stavroula Mougiakakou